About 75% of organizations in the life sciences sector have adopted AI technologies within the last two years, largely driven by the rise of generative AI.

A recent survey by Arnold & Porter reveals that over 85% of life sciences companies plan to fully implement AI tools within the next two years.

Research and development remains the most common area for AI application, with 79% of respondents utilizing AI to enhance drug discovery and clinical trials.

Approximately half of the surveyed companies are leveraging AI to optimize product discovery, noting faster time-to-market and improved efficiency as significant benefits.

AI is also being integrated into manufacturing, marketing, and regulatory functions, with 62%, 45%, and 42% of respondents respectively reporting its use to enhance efficiency across the product lifecycle.

Despite the growing adoption of AI, only 55% of companies have established formal AI policies, and just 51% conduct regular audits or have cross-functional teams for governance.

Concerns regarding intellectual property challenges related to AI are rising, with 74% of respondents expressing worries about new IP issues emerging in the coming year.

Studies indicate that AI can outperform physicians in certain diagnostic tasks, highlighting the need for better integration of AI tools in clinical settings.

The role of AI in patient care and diagnostics is expected to grow, with AI-assisted tools likely becoming standard in healthcare, although regulatory scrutiny is anticipated.

Recent discussions in the healthcare AI space emphasize the importance of careful implementation and learning from military medicine to enhance healthcare practices.

As regulatory scrutiny regarding AI use intensifies, companies are prompted to address governance and compliance challenges associated with their AI technologies.

The European Union's AI Act is approaching key compliance deadlines, reflecting the urgent need for timely regulation in the AI space.